Kenichi Kazuta

A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term <scp>ASP1941</scp> Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

Atsunori Kashiwagi, Hideyuki Takahashi, Hiroshi Ishikawa et al. · Diabetes Obesity and Metabolism · 2014 · 113 citations · Full text

Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

Atsunori Kashiwagi, Kenichi Kazuta, Satoshi Yoshida et al. · Journal of Diabetes Investigation · 2013 · 98 citations · Full text

Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study

Atsunori Kashiwagi, Kenichi Kazuta, Yuusuke Takinami et al. · Diabetology International · 2014 · 81 citations

Obesity, Metabolic Syndrome, Diabetes Management +5

Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study

Atsunori Kashiwagi, Noriko Akiyama, Takanori Shiga et al. · Diabetology International · 2014 · 59 citations

Metabolic Syndrome, Diabetes Management, Diabetes +6

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Atsunori Kashiwagi, Takanori Shiga, Noriko Akiyama et al. · Diabetology International · 2014 · 52 citations

Metabolic Syndrome, Diabetes Management, Spotlight Study +8